BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soyka M, Müller CA. Pharmacotherapy of alcoholism – an update on approved and off-label medications. Expert Opinion on Pharmacotherapy 2017;18:1187-99. [DOI: 10.1080/14656566.2017.1349098] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Fischler PV, Soyka M, Seifritz E, Mutschler J. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol 2022;13:927703. [DOI: 10.3389/fphar.2022.927703] [Reference Citation Analysis]
2 Yang W, Singla R, Maheshwari O, Fontaine CJ, Gil-mohapel J. Alcohol Use Disorder: Neurobiology and Therapeutics. Biomedicines 2022;10:1192. [DOI: 10.3390/biomedicines10051192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chi FW, Parthasarathy S, Palzes VA, Kline-Simon AH, Metz VE, Weisner C, Satre DD, Campbell CI, Elson J, Ross TB, Lu Y, Sterling SA. Alcohol brief intervention, specialty treatment and drinking outcomes at 12 months: Results from a systematic alcohol screening and brief intervention initiative in adult primary care. Drug Alcohol Depend 2022;235:109458. [PMID: 35453082 DOI: 10.1016/j.drugalcdep.2022.109458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yuan J, Wu C, Wu L, Fan X, Zeng T, Xu L, Wei Y, Zhang Y, Wang H, Peng Y, Kang C, Yang J. The Association of P300 Components With Clinical Characteristics and Efficacy of Pharmacotherapy in Alcohol Use Disorder. Front Psychiatry 2022;13:770714. [DOI: 10.3389/fpsyt.2022.770714] [Reference Citation Analysis]
5 Monroy-Jaramillo N, Martínez-Magaña JJ, Pérez-Aldana BE, Ortega-Vázquez A, Montalvo-Ortiz J, López-López M. The role of alcohol intake in the pharmacogenetics of treatment with clozapine. Pharmacogenomics 2022;23:371-92. [PMID: 35311547 DOI: 10.2217/pgs-2022-0006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang Y, Qiu Y, Zhang H. Computational Investigation of Structural Basis for Enhanced Binding of Isoflavone Analogues with Mitochondrial Aldehyde Dehydrogenase. ACS Omega 2022;7:8115-27. [PMID: 35284766 DOI: 10.1021/acsomega.2c00032] [Reference Citation Analysis]
7 Quijano Cardé NA, Perez EE, Feinn R, Kranzler HR, De Biasi M. Antagonism of GluK1-containing kainate receptors reduces ethanol consumption by modulating ethanol reward and withdrawal. Neuropharmacology 2021;199:108783. [PMID: 34509497 DOI: 10.1016/j.neuropharm.2021.108783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mitoma H, Manto M, Shaikh AG. Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum. Int J Environ Res Public Health 2021;18:8678. [PMID: 34444449 DOI: 10.3390/ijerph18168678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Abozaid A, Hung J, Tsang B, Motlana K, Al-Ani R, Gerlai R. Behavioral effects of acute ethanol in larval zebrafish (D. rerio) depend on genotype and volume of experimental well. Prog Neuropsychopharmacol Biol Psychiatry 2021;112:110411. [PMID: 34363865 DOI: 10.1016/j.pnpbp.2021.110411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Front Pharmacol 2021;12:626010. [PMID: 34093179 DOI: 10.3389/fphar.2021.626010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
11 Cardé NAQ, Perez EE, Feinn R, Kranzler HR, Biasi MD. Antagonism of GluK1-containing Kainate Receptors Reduces Ethanol Consumption by Modulating Ethanol Reward and Withdrawal.. [DOI: 10.1101/2021.04.24.441015] [Reference Citation Analysis]
12 Siska F, Amchova P, Kuruczova D, Tizabi Y, Ruda-Kucerova J. Effects of low-dose alcohol exposure in adolescence on subsequent alcohol drinking in adulthood in a rat model of depression. World J Biol Psychiatry 2021;:1-13. [PMID: 33821763 DOI: 10.1080/15622975.2021.1907717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Karl D, Bumb JM, Bach P, Dinter C, Koopmann A, Hermann D, Mann K, Kiefer F, Vollstädt-Klein S. Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder. Psychopharmacology (Berl) 2021;238:2179-89. [PMID: 33846866 DOI: 10.1007/s00213-021-05842-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Sebold M, Garbusow M, Cerci D, Chen K, Sommer C, Huys QJ, Nebe S, Rapp M, Veer IM, Zimmermann US, Smolka MN, Walter H, Heinz A, Friedel E. Association of the OPRM1 A118G polymorphism and Pavlovian-to-instrumental transfer: Clinical relevance for alcohol dependence. J Psychopharmacol 2021;35:566-78. [PMID: 33726538 DOI: 10.1177/0269881121991992] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Schnoz D, Suter PM. [CME: Harmful Alcohol Consumption in the Elderly]. Praxis (Bern 1994) 2021;110:121-30. [PMID: 33653099 DOI: 10.1024/1661-8157/a003650] [Reference Citation Analysis]
16 Campbell EJ, Lawrence AJ. It's more than just interoception: The insular cortex involvement in alcohol use disorder. J Neurochem 2021;157:1644-51. [PMID: 33486788 DOI: 10.1111/jnc.15310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
17 Kashyap B, Hanson LR, Frey Ii WH. Intranasal Insulin: a Treatment Strategy for Addiction. Neurotherapeutics 2020;17:105-15. [PMID: 31898283 DOI: 10.1007/s13311-019-00822-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
18 Soyka M, Rösner S. [Pharmacotherapy of alcohol withdrawal: update and new developments]. Nervenarzt 2021;92:57-65. [PMID: 32696076 DOI: 10.1007/s00115-020-00954-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
19 Milić J, Zeković J, Stankić D, van Beeck E, Samardžić J. Alcohol use disorder pharmacotherapy options for postmenopausal females. Assessments, Treatments and Modeling in Aging and Neurological Disease 2021. [DOI: 10.1016/b978-0-12-818000-6.00009-3] [Reference Citation Analysis]
20 Berríos-Cárcamo P, Quezada M, Quintanilla ME, Morales P, Ezquer M, Herrera-Marschitz M, Israel Y, Ezquer F. Oxidative Stress and Neuroinflammation as a Pivot in Drug Abuse. A Focus on the Therapeutic Potential of Antioxidant and Anti-Inflammatory Agents and Biomolecules. Antioxidants (Basel) 2020;9:E830. [PMID: 32899889 DOI: 10.3390/antiox9090830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
21 Wang SC, Chen YC, Chen SJ, Lee CH, Cheng CM. Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review. Int J Mol Sci 2020;21:E6413. [PMID: 32899236 DOI: 10.3390/ijms21176413] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
22 Quintero Garzola GC. The Use of Gabapentin for the Treatment of Alcohol and Tobacco Use Disorders: A Review

]]>. OAJCT 2020;Volume 12:43-60. [DOI: 10.2147/oajct.s257556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Rutkofsky IH, Fisher KA, Alvarez Villalba CL, Neuhut S. Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review. Cureus 2020. [DOI: 10.7759/cureus.8931] [Reference Citation Analysis]
24 Fairbanks J, Umbreit A, Kolla BP, Karpyak VM, Schneekloth TD, Loukianova LL, Sinha S. Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls. Mayo Clin Proc 2020;95:1964-77. [PMID: 32446635 DOI: 10.1016/j.mayocp.2020.01.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
25 Calleja-Conde J, Fernández-Calle R, Zapico JM, Ramos A, de Pascual-Teresa B, Bühler KM, Echeverry-Alzate V, Giné E, Rodríguez de Fonseca F, López-Moreno JA, Herradón G. Inhibition of Receptor Protein Tyrosine Phosphatase β/ζ Reduces Alcohol Intake in Rats. Alcohol Clin Exp Res 2020;44:1037-45. [PMID: 32154588 DOI: 10.1111/acer.14321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Suljević D, Šiljak A, Fočak M. Different outcomes of methadone maintenance therapy in rehabilitated and relapsed drug addicts: significance of liver and renal biomarkers. Drug Chem Toxicol 2022;45:470-5. [PMID: 32013636 DOI: 10.1080/01480545.2020.1722157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Muñoz-Muñoz AC, Pekol T, Schubring D, Hyland R, Johnson C, Andrade L. Characterization of an Amphetamine Interference from Gabapentin in an LC-HRMS Method. J Anal Toxicol 2020;44:36-40. [PMID: 31263895 DOI: 10.1093/jat/bkz046] [Reference Citation Analysis]
28 Petralia MC, Mazzon E, Mangano K, Fagone P, Di Marco R, Falzone L, Basile MS, Nicoletti F, Cavalli E. Transcriptomic analysis reveals moderate modulation of macrophage migration inhibitory factor superfamily genes in alcohol use disorders. Exp Ther Med 2020;19:1755-62. [PMID: 32104230 DOI: 10.3892/etm.2020.8410] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Lesch O, Walter H, König D, Vyssoki B. Typen, Dimensionen und Verläufe. Alkohol und Tabak 2020. [DOI: 10.1007/978-3-662-60284-3_6] [Reference Citation Analysis]
30 Lesch O, Walter H, Wetschka C, Hesselbrock MN, Hesselbrock V, Pombo S. Types, Dimensions and Aetiology. Alcohol and Tobacco 2020. [DOI: 10.1007/978-3-030-41941-7_6] [Reference Citation Analysis]
31 Lesch O, Walter H, Wetschka C, Hesselbrock MN, Hesselbrock V, Pombo S. Therapeutic Strategies in Alcohol and Tobacco Addiction. Alcohol and Tobacco 2020. [DOI: 10.1007/978-3-030-41941-7_9] [Reference Citation Analysis]
32 Lesch O, Walter H, Pombo S, Hesselbrock V, Hesselbrock M. Therapeutische Strategien bei Alkohol- und Tabakabhängigkeit. Alkohol und Tabak 2020. [DOI: 10.1007/978-3-662-60284-3_9] [Reference Citation Analysis]
33 Martinotti G, Pettorruso M, Montemitro C, Ekhtiari H, Hanlon CA, Spagnolo PA, Stein E, Di Giannantonio M. Repetitive Transcranial Magnetic Stimulation in Addiction. Non Invasive Brain Stimulation in Psychiatry and Clinical Neurosciences 2020. [DOI: 10.1007/978-3-030-43356-7_11] [Reference Citation Analysis]
34 Ballesta A, Alén F, Rodríguez de Fonseca F, Gómez de Heras R, Orio L. Rethinking the Use of Antidepressants to Treat Alcohol Use Disorders and Depression Comorbidity: The Role of Neurogenesis. Antidepressants - Preclinical, Clinical and Translational Aspects 2019. [DOI: 10.5772/intechopen.83743] [Reference Citation Analysis]
35 Pohanka M. Antidotes Against Methanol Poisoning: A Review. Mini Rev Med Chem 2019;19:1126-33. [PMID: 30864518 DOI: 10.2174/1389557519666190312150407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Knox J, Hasin DS, Larson FRR, Kranzler HR. Prevention, screening, and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry 2019;6:1054-67. [PMID: 31630982 DOI: 10.1016/S2215-0366(19)30213-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 15.7] [Reference Citation Analysis]
37 Gál BI, Kilencz T, Albert A, Demeter I, Hegedűs KM, Janka Z, Csifcsák G, Álmos PZ. Mild Effect of Nalmefene on Alcoholic Cue-Induced Response Invigoration in Alcohol Use Disorder Without Accompanying Changes in Electrophysiological Signatures of Early Visual Processing and Executive Control. Front Pharmacol 2019;10:1087. [PMID: 31611789 DOI: 10.3389/fphar.2019.01087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Hayat A, Piper BJ. Characteristics of Patients that Substitute Medical Cannabis for Alcohol.. [DOI: 10.1101/19003798] [Reference Citation Analysis]
39 Zastrozhin MS, Skryabin VY, Miroshkin SS, Bryun EA, Sychev DA. Pharmacogenetics of alcohol addiction: current perspectives. Appl Clin Genet 2019;12:131-40. [PMID: 31372024 DOI: 10.2147/TACG.S206745] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
40 Hartwell EE, Kranzler HR. Pharmacogenetics of alcohol use disorder treatments: an update. Expert Opin Drug Metab Toxicol 2019;15:553-64. [PMID: 31162983 DOI: 10.1080/17425255.2019.1628218] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
41 Soyka M, Mutschler J, Rösner S. Craving mildern. DNP 2019;20:42-47. [DOI: 10.1007/s15202-019-2204-x] [Reference Citation Analysis]
42 De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, Maurage P, Cottencin O, Carrieri PM, Rolland B. Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain. Front Pharmacol 2019;10:627. [PMID: 31214036 DOI: 10.3389/fphar.2019.00627] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
43 Cannella N, Ubaldi M, Masi A, Bramucci M, Roberto M, Bifone A, Ciccocioppo R. Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. Neurosci Biobehav Rev 2019;103:384-98. [PMID: 31112713 DOI: 10.1016/j.neubiorev.2019.05.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
44 Meckel KR, Kiraly DD. A potential role for the gut microbiome in substance use disorders. Psychopharmacology (Berl) 2019;236:1513-30. [PMID: 30982128 DOI: 10.1007/s00213-019-05232-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 21.0] [Reference Citation Analysis]
45 Brunchmann A, Thomsen M, Fink-Jensen A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review. Physiol Behav 2019;206:232-42. [PMID: 30946836 DOI: 10.1016/j.physbeh.2019.03.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
46 Waeiss RA, Knight CP, Hauser SR, Pratt LA, McBride WJ, Rodd ZA. Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. Psychopharmacology (Berl) 2019;236:1887-900. [PMID: 30758525 DOI: 10.1007/s00213-019-5174-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
47 Supasitthumrong T, Bolea-Alamanac BM, Asmer S, Woo VL, Abdool PS, Davies SJC. Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report. Br J Clin Pharmacol 2019;85:690-703. [PMID: 30575088 DOI: 10.1111/bcp.13844] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
48 Crowley NA, Magee SN, Feng M, Jefferson SJ, Morris CJ, Dao NC, Brockway DF, Luscher B. Ketamine normalizes binge drinking-induced defects in glutamatergic synaptic transmission and ethanol drinking behavior in female but not male mice. Neuropharmacology 2019;149:35-44. [PMID: 30731135 DOI: 10.1016/j.neuropharm.2019.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
49 Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clin Exp Res 2019;43:522-30. [PMID: 30620410 DOI: 10.1111/acer.13953] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
50 Diana M, Bolloni C, Antonelli M, Di Giuda D, Cocciolillo F, Fattore L, Addolorato G. Repetitive transcranial magnetic stimulation: Re-wiring the alcoholic human brain. Alcohol 2019;74:113-24. [PMID: 30420113 DOI: 10.1016/j.alcohol.2018.05.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
51 Witkin JM, Wallace TL, Martin WJ. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094). In: Ko M, Caló G, editors. The Nociceptin/Orphanin FQ Peptide Receptor. Cham: Springer International Publishing; 2019. pp. 399-415. [DOI: 10.1007/164_2018_186] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
52 Rivera-meza M. The Hyperpolarization-Activated Cyclic Nucleotide-Gated Ion Channels in the Rewarding Effects of Ethanol. Neuroscience of Alcohol 2019. [DOI: 10.1016/b978-0-12-813125-1.00018-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Mutschler J, Müller CA, Soyka M. Alkohol. Suchtmedizin 2019. [DOI: 10.1016/b978-3-437-23021-9.00007-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Chompookham P, Rukngan W, Nilaban S, Suwanmajo S, Yoosom P, Kalayasiri R. A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence. Psychiatry Research 2018;270:34-40. [DOI: 10.1016/j.psychres.2018.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
55 Soyka M. Diagnostik und Therapie der Alkoholabhängigkeit. DNP 2018;19:53-59. [DOI: 10.1007/s15202-018-1885-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Blanco-gandía MC, Rodríguez-arias M. Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. European Journal of Pharmacology 2018;836:89-101. [DOI: 10.1016/j.ejphar.2018.08.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
57 Agabio R, Leggio L. Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders. Front Psychiatry 2018;9:464. [PMID: 30323774 DOI: 10.3389/fpsyt.2018.00464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
58 Hofford RS, Russo SJ, Kiraly DD. Neuroimmune mechanisms of psychostimulant and opioid use disorders. Eur J Neurosci 2019;50:2562-73. [PMID: 30179286 DOI: 10.1111/ejn.14143] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
59 Alen F, Decara J, Brunori G, You ZB, Bühler KM, López-Moreno JA, Cippitelli A, Pavon FJ, Suárez J, Gardner EL, de la Torre R, Ciccocioppo R, Serrano A, Rodríguez de Fonseca F. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochem Pharmacol 2018;157:235-43. [PMID: 30195735 DOI: 10.1016/j.bcp.2018.09.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
60 González-marín MC, Lebourgeois S, Jeanblanc J, Diouf M, Naassila M. Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking. Neuropharmacology 2018;140:14-24. [DOI: 10.1016/j.neuropharm.2018.07.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
61 Campbell EJ, Marchant NJ, Lawrence AJ. A sleeping giant: Suvorexant for the treatment of alcohol use disorder? Brain Res 2020;1731:145902. [PMID: 30081035 DOI: 10.1016/j.brainres.2018.08.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
62 Wang W, Xu Y, Jiang C, Gao Y. Advances in the treatment of severe alcoholic hepatitis. Curr Med Res Opin 2019;35:261-73. [PMID: 29781336 DOI: 10.1080/03007995.2018.1479247] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
63 Beggiato S, Borelli AC, Tomasini MC, Castelli MP, Pintori N, Cacciaglia R, Loche A, Ferraro L. In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5. Front Pharmacol 2018;9:327. [PMID: 29674969 DOI: 10.3389/fphar.2018.00327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Campbell EJ, Lawrence AJ, Perry CJ. New steps for treating alcohol use disorder. Psychopharmacology 2018;235:1759-73. [DOI: 10.1007/s00213-018-4887-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
65 Khoja S, Huynh N, Warnecke AMP, Asatryan L, Jakowec MW, Davies DL. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology (Berl) 2018;235:1697-709. [PMID: 29500584 DOI: 10.1007/s00213-018-4869-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
66 Haass-Koffler CL, Swift RM, Leggio L. Noradrenergic targets for the treatment of alcohol use disorder. Psychopharmacology (Berl) 2018;235:1625-34. [PMID: 29460163 DOI: 10.1007/s00213-018-4843-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
67 Witkiewitz K, Vowles KE. Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review. Alcohol Clin Exp Res 2018;42:478-88. [PMID: 29314075 DOI: 10.1111/acer.13594] [Cited by in Crossref: 94] [Cited by in F6Publishing: 120] [Article Influence: 23.5] [Reference Citation Analysis]